Information Provided By:
Fly News Breaks for November 6, 2019
Nov 6, 2019 | 07:53 EDT
Jefferies analyst David Steinberg downgraded Supernus Pharmaceuticals to Hold from Buy with a price target of $23, down from $46. The company's revenue and earnings in Q3 were below estimates and the SPN-810 Phase 3 date in attention deficit hyperactivity disorder impulse aggression missed, Steinberg tells investors in a research note. Further, the SPN-812 new drug application has yet to be filed, adds the analyst.
News For SUPN From the Last 2 Days
There are no results for your query SUPN